IS6630A - 5-klór-3-(4-metansúlfónýlfenýl)-6'-metýl-[2,3']bípýridinýl á hreinu kristallaformi og aðferð til smíði þess - Google Patents

5-klór-3-(4-metansúlfónýlfenýl)-6'-metýl-[2,3']bípýridinýl á hreinu kristallaformi og aðferð til smíði þess

Info

Publication number: IS6630A
Authority: IS; Iceland
Prior art keywords: methanesulfonylphenyl; bipyridinyl; chloro; methyl; construction
Prior art date: 2000-05-26

Application number

IS6630A

Other languages

English (en)

Other versions

IS2806B (is

Inventor

S. Crocker Louis

W. Davies Ian

G. Osifchin Richard

Kotliar Andrew

Original Assignee

Merck & Co., Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-26

Filing date

2002-11-20

Publication date

2002-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-11-20 Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.

2002-11-20 Publication of IS6630A publication Critical patent/IS6630A/is

2012-09-15 Publication of IS2806B publication Critical patent/IS2806B/is

Links

238000010276 construction Methods 0.000 title 1
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical group C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 title 1
238000000034 method Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Pulmonology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IS6630A 2000-05-26 2002-11-20 5-klór-3-(4-metansúlfónýlfenýl)-6'-metýl-[2,3']bípýridínýl á hreinu kristallaformi og aðferð til efnasmíði IS2806B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20801700P	2000-05-26	2000-05-26
PCT/US2001/016566 WO2001092230A1 (en)	2000-05-26	2001-05-22	5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis

Publications (2)

Publication Number	Publication Date
IS6630A true IS6630A (is)	2002-11-20
IS2806B IS2806B (is)	2012-09-15

Family

ID=22772880

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6630A IS2806B (is)	2000-05-26	2002-11-20	5-klór-3-(4-metansúlfónýlfenýl)-6'-metýl-[2,3']bípýridínýl á hreinu kristallaformi og aðferð til efnasmíði

Country Status (48)

Country	Link
EP (1)	EP1296951B1 (is)
JP (2)	JP3665053B2 (is)
KR (1)	KR100757699B1 (is)
CN (1)	CN1227233C (is)
AR (1)	AR028577A1 (is)
AT (1)	ATE483687T1 (is)
AU (2)	AU2001264804B2 (is)
BG (1)	BG65855B1 (is)
BR (1)	BRPI0111140B8 (is)
CA (1)	CA2410234C (is)
CR (1)	CR6606A (is)
CY (1)	CY1111440T1 (is)
CZ (1)	CZ20023888A3 (is)
DE (1)	DE60143197D1 (is)
DK (1)	DK1296951T3 (is)
EA (1)	EA004809B1 (is)
EE (1)	EE05242B1 (is)
EG (1)	EG24189A (is)
ES (1)	ES2351958T3 (is)
GC (1)	GC0000362A (is)
GE (1)	GEP20053492B (is)
GT (1)	GT200100091A (is)
HN (1)	HN2001000110A (is)
HR (1)	HRP20020934B1 (is)
HU (1)	HU228423B1 (is)
IL (1)	IL152582A0 (is)
IN (2)	IN2002CH02089A (is)
IS (1)	IS2806B (is)
JO (1)	JO2216B1 (is)
MA (1)	MA26919A1 (is)
ME (1)	ME00428B (is)
MX (1)	MX230696B (is)
MY (1)	MY123569A (is)
NO (1)	NO324495B1 (is)
NZ (1)	NZ522394A (is)
PA (1)	PA8516901A1 (is)
PE (1)	PE20011324A1 (is)
PH (1)	PH12001001175B1 (is)
PL (1)	PL358153A1 (is)
PT (1)	PT1296951E (is)
RS (1)	RS51541B (is)
SI (1)	SI1296951T1 (is)
SK (1)	SK287174B6 (is)
SV (1)	SV2002000462A (is)
TW (1)	TWI303634B (is)
UA (1)	UA73355C2 (is)
WO (1)	WO2001092230A1 (is)
ZA (1)	ZA200209558B (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2391650C (en)	1999-11-29	2011-01-25	Merck & Co., Inc.	Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
US6858631B1 (en)	1999-11-29	2005-02-22	Merck & Co., Inc.	Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
US6521642B2 (en) *	2000-05-26	2003-02-18	Merck & Co., Inc.	5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
HUE028730T2 (en)	2009-02-27	2017-01-30	Cadila Healthcare Ltd	Process for the preparation of etoricoxib
WO2012004677A1 (en)	2010-07-05	2012-01-12	Actavis Group Ptc Ehf	Solid state forms of etoricoxib salts
WO2012163839A1 (en)	2011-05-27	2012-12-06	Farma Grs, D.O.O.	A process for the preparation of polymorphic form i of etoricoxib
EP2773618A1 (en)	2011-11-03	2014-09-10	Cadila Healthcare Limited	An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en)	2011-11-21	2013-05-30	Synthon Bv	Process for making crystalline form i of etoricoxib
EP2601952A1 (en)	2011-12-07	2013-06-12	Zentiva, k.s.	Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
HUE033525T2 (en)	2012-08-27	2017-12-28	Cadila Healthcare Ltd	Pharmaceuticals containing Etoricoxib
WO2014041558A2 (en)	2012-08-27	2014-03-20	Glenmark Pharmaceuticals Limited; Glenmark Generics Limited	Process for preparation of crystalline etoricoxib
CN104418799A (zh) *	2013-09-03	2015-03-18	天津药物研究院	一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en)	2013-09-13	2015-03-19	Synthon B.V.	Process for making etoricoxib
CN106632003B (zh) *	2015-12-31	2019-02-12	上海博志研新药物技术有限公司	一种依托考昔的制备方法
CN108069896B (zh) *	2016-11-11	2022-08-12	昆明积大制药股份有限公司	一种依托考昔晶型的制备方法
CN107417599B (zh) *	2017-06-21	2020-06-09	四川尚锐生物医药有限公司	一种依托考昔晶型的制备方法
CN107056691B (zh) *	2017-06-21	2020-03-10	四川尚锐生物医药有限公司	一种制备依托考昔晶型v的方法
MX2017009660A (es)	2017-07-26	2017-11-23	Laboratorios Liomont S A De C V	Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor.
CN107556231A (zh) *	2017-09-23	2018-01-09	江苏正大清江制药有限公司	一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法
CN107417600A (zh) *	2017-09-26	2017-12-01	江苏正大清江制药有限公司	一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法
CN107898787B (zh) *	2017-12-15	2018-11-30	扬子江药业集团上海海尼药业有限公司	一种药物组合物及其制剂和制备方法
WO2019130049A1 (en)	2017-12-29	2019-07-04	Grünenthal GmbH	Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
CN110143915A (zh) *	2019-06-03	2019-08-20	蚌埠学院	一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5593994A (en) *	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
US5739166A (en) *	1994-11-29	1998-04-14	G.D. Searle & Co.	Substituted terphenyl compounds for the treatment of inflammation
SI0912518T1 (en) *	1996-07-18	2003-12-31	Merck Frosst Canada & Co.	Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5861419A (en) *	1996-07-18	1999-01-19	Merck Frosst Canad, Inc.	Substituted pyridines as selective cyclooxygenase-2 inhibitors
UA57143C2 (uk) *	1998-04-24	2003-06-16	Мерк Енд Ко., Інк.	Спосіб синтезу інгібіторів сох-2 (циклооксигенази-2) та проміжні сполуки для їх одержання
CA2391650C (en) *	1999-11-29	2011-01-25	Merck & Co., Inc.	Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

2001
- 2001-05-15 PH PH12001001175A patent/PH12001001175B1/en unknown
- 2001-05-16 AR ARP010102327A patent/AR028577A1/es unknown
- 2001-05-16 TW TW090111718A patent/TWI303634B/zh not_active IP Right Cessation
- 2001-05-16 GC GCP20011369 patent/GC0000362A/en active
- 2001-05-17 PE PE2001000443A patent/PE20011324A1/es not_active Application Discontinuation
- 2001-05-18 MY MYPI20012375 patent/MY123569A/en unknown
- 2001-05-21 GT GT200100091A patent/GT200100091A/es unknown
- 2001-05-22 ES ES01939267T patent/ES2351958T3/es not_active Expired - Lifetime
- 2001-05-22 BR BR0111140-0 patent/BRPI0111140B8/pt not_active IP Right Cessation
- 2001-05-22 EA EA200201264A patent/EA004809B1/ru not_active IP Right Cessation
- 2001-05-22 DE DE60143197T patent/DE60143197D1/de not_active Expired - Lifetime
- 2001-05-22 CN CNB018101372A patent/CN1227233C/zh not_active Ceased
- 2001-05-22 CA CA002410234A patent/CA2410234C/en not_active Expired - Lifetime
- 2001-05-22 AT AT01939267T patent/ATE483687T1/de active
- 2001-05-22 EG EG20010540A patent/EG24189A/xx active
- 2001-05-22 PT PT01939267T patent/PT1296951E/pt unknown
- 2001-05-22 GE GE5012A patent/GEP20053492B/en unknown
- 2001-05-22 IL IL15258201A patent/IL152582A0/xx active IP Right Grant
- 2001-05-22 PA PA20018516901A patent/PA8516901A1/es unknown
- 2001-05-22 WO PCT/US2001/016566 patent/WO2001092230A1/en not_active Ceased
- 2001-05-22 AU AU2001264804A patent/AU2001264804B2/en not_active Expired
- 2001-05-22 HR HR20020934A patent/HRP20020934B1/xx not_active IP Right Cessation
- 2001-05-22 RS YUP-894/02A patent/RS51541B/sr unknown
- 2001-05-22 NZ NZ522394A patent/NZ522394A/en not_active IP Right Cessation
- 2001-05-22 PL PL01358153A patent/PL358153A1/xx not_active Application Discontinuation
- 2001-05-22 UA UA20021210537A patent/UA73355C2/uk unknown
- 2001-05-22 EE EEP200200655A patent/EE05242B1/xx unknown
- 2001-05-22 HU HU0302336A patent/HU228423B1/hu unknown
- 2001-05-22 AU AU6480401A patent/AU6480401A/xx active Pending
- 2001-05-22 ME MEP-2008-638A patent/ME00428B/me unknown
- 2001-05-22 JP JP2002500844A patent/JP3665053B2/ja not_active Expired - Lifetime
- 2001-05-22 MX MXPA02011619 patent/MX230696B/es active IP Right Grant
- 2001-05-22 SK SK1670-2002A patent/SK287174B6/sk not_active IP Right Cessation
- 2001-05-22 JO JO200179A patent/JO2216B1/en active
- 2001-05-22 KR KR20027015871A patent/KR100757699B1/ko not_active Expired - Lifetime
- 2001-05-22 DK DK01939267.9T patent/DK1296951T3/da active
- 2001-05-22 CZ CZ20023888A patent/CZ20023888A3/cs unknown
- 2001-05-22 SI SI200130982T patent/SI1296951T1/sl unknown
- 2001-05-22 EP EP01939267A patent/EP1296951B1/en not_active Expired - Lifetime
- 2001-05-23 HN HN2001000110A patent/HN2001000110A/es unknown
- 2001-05-23 SV SV2001000462A patent/SV2002000462A/es active IP Right Grant
2002
- 2002-03-08 CR CR6606A patent/CR6606A/es unknown
- 2002-10-31 BG BG107237A patent/BG65855B1/bg unknown
- 2002-11-20 IS IS6630A patent/IS2806B/is unknown
- 2002-11-25 ZA ZA200209558A patent/ZA200209558B/en unknown
- 2002-11-26 NO NO20025674A patent/NO324495B1/no not_active IP Right Cessation
- 2002-12-16 IN IN2089CH2002 patent/IN2002CH02089A/en unknown
- 2002-12-23 MA MA26971A patent/MA26919A1/fr unknown
2004
- 2004-09-10 JP JP2004263913A patent/JP4142621B2/ja not_active Expired - Lifetime
2007
- 2007-11-12 IN IN5103CH2007 patent/IN2007CH05103A/en unknown
2011
- 2011-01-04 CY CY20111100010T patent/CY1111440T1/el unknown

Also Published As

Publication number	Publication date
PT1296951E (pt)	2010-12-07
CY1111440T1 (el)	2015-08-05
WO2001092230A1 (en)	2001-12-06
JP2004501116A (ja)	2004-01-15
EP1296951B1 (en)	2010-10-06
AU6480401A (en)	2001-12-11
ZA200209558B (en)	2003-10-28
CZ20023888A3 (cs)	2003-02-12
JP2005047927A (ja)	2005-02-24
NZ522394A (en)	2004-05-28
MA26919A1 (fr)	2004-12-20
SV2002000462A (es)	2002-03-08
ATE483687T1 (de)	2010-10-15
PA8516901A1 (es)	2002-04-25
IS2806B (is)	2012-09-15
EA200201264A1 (ru)	2003-04-24
ES2351958T3 (es)	2011-02-14
NO324495B1 (no)	2007-10-29
IL152582A0 (en)	2003-05-29
DE60143197D1 (de)	2010-11-18
GEP20053492B (en)	2005-04-25
PH12001001175B1 (en)	2006-08-10
EA004809B1 (ru)	2004-08-26
HN2001000110A (es)	2002-03-06
EE05242B1 (et)	2009-12-15
AR028577A1 (es)	2003-05-14
EE200200655A (et)	2004-08-16
TWI303634B (en)	2008-12-01
GC0000362A (en)	2007-03-31
JP3665053B2 (ja)	2005-06-29
SI1296951T1 (sl)	2011-01-31
KR100757699B1 (ko)	2007-09-13
PE20011324A1 (es)	2002-01-28
BG65855B1 (bg)	2010-03-31
YU89402A (sh)	2005-11-28
HRP20020934A2 (en)	2005-02-28
HRP20020934B1 (en)	2012-01-31
CA2410234A1 (en)	2001-12-06
JP4142621B2 (ja)	2008-09-03
EP1296951A1 (en)	2003-04-02
CR6606A (es)	2006-02-06
RS51541B (sr)	2011-06-30
IN2002CH02089A (is)	2005-02-25
NO20025674D0 (no)	2002-11-26
HK1058932A1 (en)	2004-06-11
SK287174B6 (sk)	2010-02-08
MY123569A (en)	2006-05-31
CN1227233C (zh)	2005-11-16
KR20030003762A (ko)	2003-01-10
PL358153A1 (en)	2004-08-09
CN1443168A (zh)	2003-09-17
BRPI0111140B1 (pt)	2018-03-13
EG24189A (en)	2008-10-08
IN2007CH05103A (is)	2008-08-27
JO2216B1 (en)	2004-10-07
DK1296951T3 (da)	2011-01-24
ME00428B (me)	2011-10-10
MXPA02011619A (es)	2003-03-27
AU2001264804B2 (en)	2006-04-06
SK16702002A3 (sk)	2003-05-02
BR0111140A (pt)	2005-01-11
NO20025674L (no)	2002-11-26
HU228423B1 (en)	2013-03-28
CA2410234C (en)	2008-05-13
BG107237A (bg)	2003-05-30
UA73355C2 (en)	2005-07-15
MX230696B (es)	2005-09-19
GT200100091A (es)	2001-12-28
BRPI0111140B8 (pt)	2021-05-25
HUP0302336A2 (hu)	2003-11-28

Publication	Publication Date	Title
IS2806B (is)	2012-09-15	5-klór-3-(4-metansúlfónýlfenýl)-6'-metýl-[2,3']bípýridínýl á hreinu kristallaformi og aðferð til efnasmíði
DK199900554A (da)	2000-01-03	Paroxetinsalte, fremgangsmåde til fremstilling deraf, farmaceutiske præparater omfattende disse og anvendelser deraf
DK1180518T3 (da)	2007-05-21	5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
NO20032332D0 (no)	2003-05-22	Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav
DK200300344U1 (da)	2003-12-12	Amlodipinmaleat og farmaceutisk præparat indeholdende amlodipinmaleat
ATE466485T1 (de)	2010-05-15	Lebensmittel enthaltend eine gelzusammensetzung sowie herstellungsverfahren
NO20015659L (no)	2002-01-18	Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
DK1334106T3 (da)	2006-09-18	Imidazolderivater, fremstillingsmetoder deraf og anvendelse deraf
PL356911A1 (en)	2004-07-12	Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
DK1122254T3 (da)	2005-08-29	4-sulfonamidpiperidinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
IL154240A0 (en)	2003-07-31	4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
DK1282639T3 (da)	2005-12-12	Polyamidnucleinsyrederivater, midler og fremgangsmåder til fremstilling heraf
NO20031272L (no)	2003-05-19	Fremgangsmåte og form for kald isopressing
DK1261625T3 (da)	2006-04-18	Memnopeptider, en fremgangsmåde til deres fremstilling og deres anvendelse
IS7844A (is)	2005-05-12	Kristallskennd fumarat sölt af 1-asabísýkló[2.2.2]okt setnu fúró[2,3-c]pýridínýl karboxamíði og samsetningar og framleiðsla þeirra
IL162524A0 (en)	2005-11-20	Derivatives of (pyridin-3-yl)-1-azabicycloÄ3.2.1Ü octane, their preparation and their terapeutic application
DK1086077T3 (da)	2004-08-02	Hidtil ukendte antiestrogener, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
NO20031108L (no)	2003-05-08	Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
NO20014393L (no)	2001-11-08	1,3,4-oksadiazol-derivater og fremgangsmåte for fremstilling av disse
PT1192163E (pt)	2004-01-30	Ditiepino¬6,5-b\|piridinas e composicoes e metodos relacionados
DK1259523T3 (da)	2004-03-22	Pluraflaviner og derivater deraf, fremgangsmåde til fremstilling og anvendelse deraf
IL156160A0 (en)	2003-12-23	Klainetins and their derivatives, method for their preparation and use thereof
DK1146044T3 (da)	2004-12-27	CNS-aktive cyclobutaindolcarboxamidderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO20022482L (no)	2002-07-24	2-arylkinolinderivater, fremgangsmåte og terapeutisk anvendelse derav
NO20011921D0 (no)	2001-04-19	Sulfidoamidokarboksylsyrer, metoder for fremstilling derav og anvendelser derav